This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooke, G. E. Articles by Leier, C. V. Search for Related Content PubMed PubMed Citation Articles by Cooke, G. E. Articles by Leier, C. V.

CLINICAL STUDIES

Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients

^a Division of Cardiology and The Heart and Lung Institute, Department of Internal Medicine, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, USA

Manuscript received November 24, 1999; revised manuscript received February 11, 2000, accepted April 5, 2000.

Reprint requests and correspondence: Dr. Carl V. Leier, Division of Cardiology, The Ohio State University, 6th Floor Means Hall, 1654 Upham Drive, Columbus, Ohio 43210
Leier-1{at}medctr.osu.edu

OBJECTIVES

We hypothesized that plasma factors important for the development of atherosclerosis play a major role in the occurrence of cardiac allograft vasculopathy (CAV).

BACKGROUND

Cardiac allograft vasculopathy is a major cause of death among heart transplant recipients, has a poorly understood pathogenesis and has similarities to atherosclerotic coronary disease.

METHODS

The study population consisted of 93 postcardiac transplant recipients. Thirty-one patients with congestive heart failure (CHF) and 18 healthy individuals served as control subjects. Posttransplant coronary anatomy was evaluated by angiography and intravascular ultrasound. Laboratory analyses of lipids, homocysteine, vitamin B₁₂ and folate, fibrinogen, vonWillebrand factor antigen (vWFAg) and renin were obtained on all participants.

RESULTS

Posttransplant patients were found to have elevated serum triglycerides, total cholesterol/high-density lipoprotein cholesterol ratio, lipoprotein (a), homocysteine, vWFAg, fibrinogen and renin and lower high-density lipoprotein cholesterol. Most of these laboratory atherogenic factors were also elevated to a similar degree in the CHF control population. Although most atherogenic markers were elevated, there was little correlation with CAV severity. Cardiac allograft vasculopathy severity varied with time after transplantation, 3-hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor use and prior cytomegalovirus infection. Even within the normal range, lower RBC folate levels were associated with increased severity of CAV.

CONCLUSIONS

The posttransplant course is associated with increased clinical and laboratory atherogenic factors, some of which likely contribute to the severity of coronary vasculopathy. Compared with normal control subjects, many of these markers are already increased in pretransplant CHF patients with or without occlusive coronary artery disease.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   CAD = coronary artery disease   CAV = cardiac allograft vasculopathy   CHF = congestive heart failure   CMV = cytomegalovirus   HDL = high-density lipoprotein   ICUS = intracoronary ultrasound   LDL = low-density lipoprotein   NYHA = New York Heart Association   vWFAg = vonWillebrand factor antigen

This article has been cited by other articles:

				C. V. Leier and G. J. Haas Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39. [Full Text] [PDF]

				K. Nasir, M. Tsai, B. D. Rosen, V. Fernandes, D. A. Bluemke, A. R. Folsom, and J. A.C. Lima Elevated Homocysteine Is Associated With Reduced Regional Left Ventricular Function: The Multi-Ethnic Study of Atherosclerosis Circulation, January 16, 2007; 115(2): 180 - 187. [Abstract] [Full Text] [PDF]

				A. Hognestad, K. Endresen, R. Wergeland, O. Stokke, O. Geiran, T. Holm, S. Simonsen, J. K. Kjekshus, and A. K. Andreassen Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients J. Am. Coll. Cardiol., August 6, 2003; 42(3): 477 - 482. [Abstract] [Full Text] [PDF]

				R. S. Vasan, A. Beiser, R. B. D'Agostino, D. Levy, J. Selhub, P. F. Jacques, I. H. Rosenberg, and P. W. F. Wilson Plasma Homocysteine and Risk for Congestive Heart Failure in Adults Without Prior Myocardial Infarction JAMA, March 12, 2003; 289(10): 1251 - 1257. [Abstract] [Full Text] [PDF]